论文部分内容阅读
目的观察重组人p53腺病毒(rAd-p53)对两种T2DM模型鼠血糖的影响,探讨rAd-p53对糖代谢的影响及机制。方法制备HFD/STZ鼠,将HFD/STZ鼠和db/db鼠各随机分为阴性对照(rAd)组、阳性对照(胰岛素)组和rAd-p53给药组,每组8只。分别依次予rAd(4×10~(10)/ml)、中效胰岛素(1 U/kg)、rAd-p53(4×10~(10)/ml)。每72 h给药1次,连续给药3次,6周后检测各组FPG、腹腔糖耐量(IPGTT)和C-P水平。结果 rAd-p53改善HFD/STZ鼠的FPG、IPGTT,并增加C-P水平(P<0.05);但以同等剂量rAd-p53和胰岛素处置db/db鼠时,对其血糖和C-P改善不明显(P>0.05),使用3倍剂量胰岛素才能改善其血糖水平(P<0.05)。结论 rAd-p53可改善HFD/STZ鼠FPG、IPGTT和C-P水平,可能与其改善胰岛β细胞分泌缺陷、增加胰岛素释放有关。
Objective To investigate the effect of rAd-p53 on blood glucose in two T2DM models and to investigate the effect of rAd-p53 on glucose metabolism and its mechanism. Methods HFD / STZ mice were randomly divided into two groups randomly: negative control group (rAd), positive control (insulin) group and rAd-p53 group. The rats were treated with rAd (4 × 10 ~ (10) / ml), insulin (1 U / kg) and rAd-p53 (4 × 10 ~ (10) / ml) Administered once every 72 h, 3 consecutive doses, 6 weeks after the test group FPG, intraperitoneal glucose tolerance (IPGTT) and C-P levels. Results rAd-p53 improved FPG and IPGTT and increased CP level in HFD / STZ mice (P <0.05). However, the blood glucose and CP did not improve significantly in rAd-p53 and insulin-treated db / db mice > 0.05), three times the dose of insulin in order to improve their blood glucose levels (P <0.05). Conclusions rAd-p53 can improve the level of FPG, IPGTT and C-P in HFD / STZ mice, which may be related to the improvement of pancreatic β-cell secretion and insulin release.